Breaking News

Last week, GenomeWeb's readers were most interested in Illumina's launch of a $650 million senior notes offering.

Diagenode said the deal will bolster its suite of epigenomics services and platforms, as well as enhance its epigenetic biomarker discovery efforts.

The consortium sequenced the bread wheat variety Chinese Spring, which has been used to develop genetic resources used by wheat researchers.

The system is designed to detect single amino acid polymorphisms in touch skin samples that can be used to identify specific people.

Funds raised through the offering will be used to buy back shares of common stock from shareholders in privately negotiated transactions.

The Genome Canada program will encourage the formation of private-public partnerships to develop gene-based technologies for healthcare and agriculture.

The acquisition will enable Tecan to expand into the genomics space by coupling NuGen's NGS sample prep kits with its own laboratory automation products.

The team also elucidated well-established and controversial non-BRCA predisposition genes associated with breast or ovarian cancer.

The groups will conduct a study evaluating the benefits of targeted next-generation sequencing in the diagnosis and care of infants with genetic disorders.

The firm will use the grant to accelerate the commercialization of synthetic DNA standards and algorithms licensed from the University of Minnesota.

The planned joint venture with Beijing Zishan Health Consultancy is aimed at bringing Genetic Technologies' genomic tests to the Chinese market.

Initial purchasers will also have a 30-day option to purchase up to an addition $100 million of the notes for a potential offering size of $750 million.

The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.

The Signatera research-use-only assay monitors cancer treatment and assesses minimal residual disease, and is customized for individual patients.

The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.

The company has struck a deal to market its tests, including ones based on its Aristotle early cancer detection platform, in collaboration with LifeX.

The company's test volume during the quarter shrank to just over 1,000 samples compared to 1,405 in the same period last year.

The firm's overall growth in the quarter was led largely by 9 percent growth in its Diagnostics and Genomics Group.

The company had no Q2 revenues and continues to advance DetermaVu, its liquid biopsy lung cancer diagnostic test, toward commercialization.

A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.

The automated, whole-genome directional genomic hybridization system can measure de novo random, low-frequency, and complex structural variations.

The test can be used on donated blood samples as well as other human cells and tissues.

Pages

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.